<DOC>
	<DOCNO>NCT00959426</DOCNO>
	<brief_summary>PF-04620110 novel compound propose treatment Type 2 diabetes mellitus . The primary purpose trial evaluate safety tolerability , pharmacokinetics , pharmacodynamics , multiple oral dos PF-04620110 .</brief_summary>
	<brief_title>A Multiple Dose Study Of PF-04620110 In Overweight And Obese , Otherwise Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year Body Mass Index ( BMI ) 26.5 35.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>- Mutliple Ascending Dose Study Overweight Subjects - Body Weight - Signs Symptoms</keyword>
</DOC>